Treatment of Major Depression
Treatment of Major Depression is a research topic within Pharmacology. Science Explorer counts 31k research works in it since 1951. 24.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the molecular mechanisms and treatment strategies for depression, with a particular emphasis on antidepressant medications, ketamine, NMDA receptor antagonists, and neurobiological pathways. It covers topics such as treatment-resistant depression, glutamate signaling, cognitive impairment, and synaptic plasticity. The papers also discuss clinical guidelines and the evaluation of outcomes for various treatment approaches.
- Depression
- Antidepressant
- Ketamine
- NMDA Receptor
- Treatment-Resistant Depression
- Neurobiological Mechanisms
- Glutamate Signaling
- Cognitive Impairment
- Synaptic Plasticity
- Clinical Guidelines
- Research works
- 31k fractional, since 1951
- In the world top 10%
- 7.3k per year above
- Top-10% rate
- 24.0% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +14% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Treatment of Major Depression research?
By volume, the United States and China publish the most (1.3k and 735 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.3k works
- 2 China 735 works
- 3 United Kingdom 282 works
- 4 Germany 235 works
- 5 Canada 233 works
- 6 India 219 works
- 7 Italy 188 works
- 8 Japan 154 works
- 9 Australia 136 works
- 10 Spain 126 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Treatment of Major Depression research?
By volume in 2022–2025, University of Toronto publishes the most Treatment of Major Depression research, followed by King's College London and Harvard University.
By volume, 2022–2025
- 1 University of TorontoCanada 34 works
- 2 King's College LondonUnited Kingdom 28 works
- 3 Harvard UniversityUnited States 26 works
- 4 Yale UniversityUnited States 24 works
- 5 Massachusetts General HospitalUnited States 22 works
- 6 Stanford UniversityUnited States 19 works
- 7 University College LondonUnited Kingdom 17 works
- 8 University of OxfordUnited Kingdom 17 works
- 9 University of PittsburghUnited States 17 works
- 10 University of California San DiegoUnited States 17 works
Who are the leading researchers in Treatment of Major Depression?
The most-cited researchers publishing on Treatment of Major Depression include Ronald C. Kessler, Dan J. Stein and Josep María Haro.
- 1 Ronald C. Kessler United States 9.8k citations
- 2 Dan J. Stein South Africa 7.7k citations
- 3 Josep María Haro Spain 6.4k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Treatment of Major Depression research done?
The largest centres of Treatment of Major Depression research in 2022–2025 are London (United Kingdom), Beijing (China), Toronto (Canada) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Bethesda and Toronto.
Largest cities, 2022–2025
Where it is the local speciality
- BethesdaUS · 31.2 works5.1×
- TorontoCA · 82.2 works4.9×
Location quotient: how much more of its research is in Treatment of Major Depression than the world average.
Where is the best place to study Treatment of Major Depression?
Among universities, judged by research, King's College London, Guangzhou Medical University and University of Toronto score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | King's College LondonUnited Kingdom | 66.3 | 30.3% | 7.7× | 28 | -5.2% |
| 2 | Guangzhou Medical UniversityChina | 64.8 | 21.7% | 10.3× | 14 | +304.4% |
| 3 | University of TorontoCanada | 60.7 | 28.1% | 4.9× | 34 | +22.3% |
| 4 | Gdańsk Medical UniversityPoland | 59.4 | 27.7% | 20.4× | 12 | +50.2% |
| 5 | Yale UniversityUnited States | 58.6 | 33.7% | 4.8× | 24 | +38.0% |
| 6 | Harvard UniversityUnited States | 57.1 | 33.8% | 4.1× | 26 | -11.3% |
| 7 | Vrije Universiteit AmsterdamNetherlands | 54.7 | 38.0% | 5.2× | 10 | +58.4% |
| 8 | University of SienaItaly | 53.2 | 18.2% | 12.7× | 12 | +55.1% |
| 9 | Karolinska InstitutetSweden | 51.6 | 23.1% | 6.3× | 14 | +25.6% |
| 10 | University College LondonUnited Kingdom | 50.9 | 34.4% | 2.6× | 17 | +18.7% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Treatment of Major Depression research growing?
Output in 2018–2022 was 14% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Treatment of Major Depression.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.